Author:
Meck Jeanne M.,Putcha Girish V.,Cherry Athena M.
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. • Gregg AR, Gross SJ, Best RG, Monaghan KG, Bajaj K, Skotko BG, Thompson BH, Watson, MS, for The noninvasive prenatal screening work group of the American College of Medical Genetics and Genomics. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med. 2013; 15:395–8. This is the policy statement by the American College of Medical Genetics regarding the utility and limitations of NIPS.
2. • The American College of Obstetricians and Gynecologists Committee on Genetics and the Society for Maternal Fetal Medicine Publications Committee. Noninvasive prenatal testing for fetal aneuploidy. Committee Opinion No 545. December 2012. This is the policy statement by the American College of Obstetrics and Gynecology regarding the utility and limitations of NIPS.
3. •• Gil MM, Quezada MS, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2015;45:249–66. Meta-analysis of 37 NIPS studies analyzing detection rates and false positive rates for various aneuploidies.
4. Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Am J Obstet Gynecol. 2012;119(5):890–901.
5. Palomaki GE, Decio C, Kolza EM, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaboration study. Genet Med. 2012;14(3):296–305.